The largest database of trusted experimental protocols

Vantage analyser

Manufactured by Siemens
Sourced in Japan, United States

The Vantage analyser is a laboratory equipment product offered by Siemens. It is designed for the analysis of various samples. The core function of the Vantage analyser is to provide accurate and reliable analytical results.

Automatically generated - may contain errors

2 protocols using vantage analyser

1

Analyzing Metabolic Markers in Cohort

Check if the same lab product or an alternative is used in the 5 most similar protocols
HbA1c was analysed locally at each centre, using DCCT aligned methods (HbA1c Variant analyser [Bio-Rad Laboratories, Hercules, CA, USA], Adams Arkray [Kyoto, Japan], Vantage analyser [Siemens Diagnostics, Camberley, UK] or DCA 2000, [Siemens Diagnostics, Tarrytown, NY, USA]). Lipid profile measurements (cholesterol, HDL-cholesterol, LDL-cholesterol, triacylglycerol) were measured using routine laboratory methods.
The standard deviation score (SDS) was calculated for height, weight and BMI according to the least-mean squares method [17 (link)]. Blood pressure was measured using an Omran M6 blood pressure monitor (Hoofddorp, the Netherlands) and/or Dinamap monitor (Tampa, FL, USA) using an appropriate sized cuff. Age- and sex-related percentiles and SDS for systolic blood pressure (SBP) and diastolic blood pressure (DBP) were calculated according to published standards [18 (link)].
This study was approved by the Human Research Ethics Committees of each participating centre. Informed consent was obtained from participants and their families.
+ Open protocol
+ Expand
2

Evaluating Antidiabetic Effects of GLP-1-gFc

Check if the same lab product or an alternative is used in the 5 most similar protocols
To evaluate the dose‐dependent antidiabetic effect of GLP‐1‐gFc in the progress of type 2 diabetes, 5‐week‐old male diabetic (C57BL/KSJ‐db/db) mice were acclimated to a feeding environment for 2 weeks. After evaluation of body weight, animals were allocated to treatment groups (n = 12/group): vehicle, 0.6 mg/kg dulaglutide, 0.6 mg/kg GLP‐1‐gFc and 1.8 mg/kg GLP‐1‐gFc. The TAs were administered subcutaneously twice a week for 4 weeks. Non‐fasting blood glucose and insulin were measured biweekly, and overnight fasting blood glucose, insulin and HbA1c were measured at sacrifice. Glucose was analysed using GM9 Glucose Analyser (Analox Instruments Ltd, UK). Insulin and HbA1c were measured by rat insulin radioimmunoassay (LINCO Research, MO, USA) and Vantage analyser (Siemens, Munich, Germany), respectively.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!